599 related articles for article (PubMed ID: 26034039)
1. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
2. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
3. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Belum VR; Wu S; Lacouture ME
Invest New Drugs; 2013 Aug; 31(4):1078-86. PubMed ID: 23700287
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
6. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial.
Jatoi A; Ou FS; Ahn DH; Zemla TJ; Le-Rademacher JG; Boland P; Ciombor KK; Jacobs NL; Pasche B; Cleary JM; McCune JS; Pedersen KS; Barzi A; Chiorean EG; Heying EN; Lenz HJ; Sloan JA; Grothey A; Lacouture ME; Bekaii-Saab T
Oncologist; 2021 Jul; 26(7):610-618. PubMed ID: 33604969
[TBL] [Abstract][Full Text] [Related]
7. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
8. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
Grothey A; George S; van Cutsem E; Blay JY; Sobrero A; Demetri GD
Oncologist; 2014 Jun; 19(6):669-80. PubMed ID: 24821824
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management.
Ai L; Xu Z; Yang B; He Q; Luo P
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1121-1127. PubMed ID: 31679411
[No Abstract] [Full Text] [Related]
10. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction.
Sato J; Ishikawa H; Hamauchi S; Yamawaki Y; Mori K; Kiyohara Y; Yoshikawa S; Yamazaki K; Yasui H; Shino M
J Oncol Pharm Pract; 2020 Mar; 26(2):361-367. PubMed ID: 31106665
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis.
Belum VR; Serna-Tamayo C; Wu S; Lacouture ME
Clin Exp Dermatol; 2016 Jan; 41(1):8-15. PubMed ID: 26009777
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
13. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
15. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Nardone B; Hensley JR; Kulik L; West DP; Mulcahy M; Rademaker A; Lacouture ME
J Drugs Dermatol; 2012 Nov; 11(11):e61-5. PubMed ID: 23135095
[TBL] [Abstract][Full Text] [Related]
16. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
17. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
18. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.
Balagula Y; Wu S; Su X; Feldman DR; Lacouture ME
Invest New Drugs; 2012 Aug; 30(4):1773-81. PubMed ID: 21394443
[TBL] [Abstract][Full Text] [Related]
19. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs).
Anderson R; Jatoi A; Robert C; Wood LS; Keating KN; Lacouture ME
Oncologist; 2009 Mar; 14(3):291-302. PubMed ID: 19276294
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial.
Nishizawa A; Shinozaki E; Wakatsuki T; Satoh T; Yamazaki N; Oyamada S; Ariyoshi K; Kihara K; Tsuboi M; Yamaguchi K
BMC Cancer; 2023 May; 23(1):401. PubMed ID: 37142953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
